FOI_8380

Internal Reference Number: FOI_8380

Date Request Received: 15/01/2025 00:00:00

Date Request Replied To: 28/01/2025 00:00:00

This response was sent via: By Email

Request Summary: Spinal Muscular Atrophy

Request Category: Researcher


Question Number 1: We have a freedom of information request related to the diagnosis and treatment of Spinal Muscular Atrophy. Your answers to the following questions would be greatly appreciated. How many patients have a current diagnosis for Spinal Muscular Atrophy (ICD-10 Code G12.0, G12.1, G12.8 and G12.9) at your trust?

Answer To Question 1: 20 patients

Question Number 2: How many patients have been treated in the last 4 months (September to December 2024) with the following products: • Evrysdi (Risdiplam) - total patients • Spinraza (Nusinersen) - total patients • Zolgensma (Onasemnogene) - total patients • Evrysdi (Risdiplam) – new* patients • Spinraza (Nusinersen) – new* patients • Zolgensma (Onasemnogene) – new* patients *new patients are defined as patients who were not treated with any of Spinraza (Nusinersen), Evrysdi (Risdiplam) or Zolgensma (Onasemnogene) in the previous 4-month period (May to August 2024).

Answer To Question 2: Response from Pharmacy: Pharmacy do not stock and have not issued any of the 3 treatments listed in this FOI Response from Spinal: We do not use any of these medications. It is prescribed by Neurologists.

Question Number 3: Of the total patients treated in the last 4 months (September to December 2024) with Evrysdi (Risdiplam), please provide the number of patients that were treated with Spinraza (Nusinersen) in the previous 4 months (May to August 2024).

Answer To Question 3: Response from Pharmacy: Pharmacy do not stock and have not issued any of the 3 treatments listed in this FOI

Question Number 4: Of the total patients treated in the last 4 months (September to December 2024) with Zolgensma (Onasemnogene), please provide the number of patients that were treated with Spinraza (Nusinersen) in the previous 4 months (May to August 2024).

Answer To Question 4: Response from Pharmacy: Pharmacy do not stock and have not issued any of the 3 treatments listed in this FOI

Question Number 5: How many patients have been treated with Zolgensma (Onasemnogene) in the last 12 months (January to December 2024)?

Answer To Question 5: Response from Pharmacy: Pharmacy do not stock and have not issued any of the 3 treatments listed in this FOI

To return to the list of all the FOI requests please click here

Our staff at Salisbury District Hospital have long been well regarded for the quality of care and treatment they provide for our patients and for their innovation, commitment and professionalism. This has been recognised in a wide range of achievements and it is reflected in our award of NHS Foundation Trust status. This is afforded to hospitals that provide the highest standards of care.